Trial
NCT04305327
Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
LEO Pharma
Collaborators
—
Condition
Psoriasis
Intervention
Brodalumab
Why stopped
Early terminated due to difficulty recruiting participants
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-14